journal of Dental Research publishes a paper directed by Salvatore Sauro, Professor at University CEU Cardenal Herrera in Spain, in collaboration with international researchers from Finland, Brazil, United States and United Kingdom. The research report has demonstrated how the use of zoledronic acid, in combination with bioactive ion-releasing resin-based restorative materials used as dental adhesive, reduces the degradation of dentin collagen and promotes remineralisation at the resin-dentin interface.
Zoledronic acid is employed as a treatment for osteoporosis and bone cancer.For the first time, Salvatore Sauro, Professor in Biomaterials and Minimally Invasive Dentistry at University CEU Cardenal Herrera Valencia (Spain), in collaboration with international researchers from Finland, Brazil, United States and United Kingdom, has demonstrated that zoledronate (zoledronic acid) in combination with bioactive ion-releasing resin-based adhesive systems can be applied in restorative dentistry as an innovative strategy to reduce the degradation of dentin collagen and enhance remineralisation processes at the resin-dentine interface.
Zoledronic acid is a class of medications called bisphosphonates. It works by slowing bone breakdown, increasing bone density and decreasing the amount of calcium released from the bones into the blood. Zoledronic acid is used to prevent or treat osteoporosis in women who have undergone menopause. It is also used to treat osteoporosis in men, and to prevent or treat osteoporosis in individuals who are taking glucocorticoids. This drug can be prescribed for the treatment of the Paget's disease of bone or high levels of calcium in the blood that may be caused by certain types of cancer. Zoledronic acid is applied in cancer chemotherapy to treat bone damage caused by multiple or by cancer that began in another part of the body but has spread to the bones. However, it is not a cancer chemotherapy, and it will not slow or stop the spread of cancer. For the first time Zoledronic acid has been tested in combination with bioactive resin-based adhesive systems and applied in restorative dentistry as an innovative strategy to reduce the degradation of dentin collagen and promote enhanced remineralisation at the resin-dentine interface.
Remineralisation properties
The research performed by Professor Sauro and his team showed that the remineralisation properties of bioactive ion-releasing resin-based materials can be potentiated when they are employed in combination with biomimetic phosphoproteins' analogues of dentine mineralization such as Zoledronic acid. It is well known that resin-hybridized dentin can be affected by the proteolytic action of host-derived matrix metalloproteinases present within the dentine matrix, also in the absence of bacterial enzymes.
However, collagen degradation within incompletely infiltrated hybrid layers may be prevented by biomimetic remineralization of the denuded collagen fibrils within the resin-dentine bonding interface.
The research team which produced this scientific data was leaded by Professor Sauro in collaboration with professor Arzu Tezvergil-Mutluay and Dr. Roda Seseogullari Dirihan from the University of Turku (Finland); Dr. Victor Feitosa, from the Federal University of Ceará (Brazil); Professors Franklin Tay and David Pashley, from Georgia Health Sciences University (United States); Professor Tim Watson from King's College London Dental Institute at Guy's Hospital (United Kingdom).
journal of Dental Research publishes a paper directed by Salvatore Sauro, Professor at University CEU Cardenal Herrera in Spain, in collaboration with international researchers from Finland, Brazil, United States and United Kingdom. The research report has demonstrated how the use of zoledronic acid, in combination with bioactive ion-releasing resin-based restorative materials used as dental adhesive, reduces the degradation of dentin collagen and promotes remineralisation at the resin-dentin interface.
Zoledronic acid is employed as a treatment for osteoporosis and bone cancer.For the first time, Salvatore Sauro, Professor in Biomaterials and Minimally Invasive Dentistry at University CEU Cardenal Herrera Valencia (Spain), in collaboration with international researchers from Finland, Brazil, United States and United Kingdom, has demonstrated that zoledronate (zoledronic acid) in combination with bioactive ion-releasing resin-based adhesive systems can be applied in restorative dentistry as an innovative strategy to reduce the degradation of dentin collagen and enhance remineralisation processes at the resin-dentine interface.
Zoledronic acid is a class of medications called bisphosphonates. It works by slowing bone breakdown, increasing bone density and decreasing the amount of calcium released from the bones into the blood. Zoledronic acid is used to prevent or treat osteoporosis in women who have undergone menopause. It is also used to treat osteoporosis in men, and to prevent or treat osteoporosis in individuals who are taking glucocorticoids. This drug can be prescribed for the treatment of the Paget's disease of bone or high levels of calcium in the blood that may be caused by certain types of cancer. Zoledronic acid is applied in cancer chemotherapy to treat bone damage caused by multiple or by cancer that began in another part of the body but has spread to the bones. However, it is not a cancer chemotherapy, and it will not slow or stop the spread of cancer. For the first time Zoledronic acid has been tested in combination with bioactive resin-based adhesive systems and applied in restorative dentistry as an innovative strategy to reduce the degradation of dentin collagen and promote enhanced remineralisation at the resin-dentine interface.
Remineralisation properties
The research performed by Professor Sauro and his team showed that the remineralisation properties of bioactive ion-releasing resin-based materials can be potentiated when they are employed in combination with biomimetic phosphoproteins' analogues of dentine mineralization such as Zoledronic acid. It is well known that resin-hybridized dentin can be affected by the proteolytic action of host-derived matrix metalloproteinases present within the dentine matrix, also in the absence of bacterial enzymes.
However, collagen degradation within incompletely infiltrated hybrid layers may be prevented by biomimetic remineralization of the denuded collagen fibrils within the resin-dentine bonding interface.
The research team which produced this scientific data was leaded by Professor Sauro in collaboration with professor Arzu Tezvergil-Mutluay and Dr. Roda Seseogullari Dirihan from the University of Turku (Finland); Dr. Victor Feitosa, from the Federal University of Ceará (Brazil); Professors Franklin Tay and David Pashley, from Georgia Health Sciences University (United States); Professor Tim Watson from King's College London Dental Institute at Guy's Hospital (United Kingdom).
การแปล กรุณารอสักครู่..
